Merck’s Keytruda wins U.S. FDA approval for bladder cancer

Author: No Comments Share:

FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo

(Reuters) – The U.S. Food and Drug Administration said on Wednesday it approved Merck & Co Inc’s Keytruda for a hard-to-treat form of bladder cancer.

The therapy was approved for patients with a high-risk non-muscle invasive bladder cancer who have undergone prior treatment and are ineligible for or have opted out of surgical removal of part of the bladder.

Non-muscle-invasive bladder cancer is commonly treated with the Bacillus Calmette-Guerin vaccine. However, patients who do not respond to the vaccine have limited non-surgical treatment options.

The approval was based on results from a mid-stage study in which nearly 41% of the patients on Keytruda showed a complete response, with about half of them having a complete response for at least a year.

Merck estimated that more than 80,000 Americans were newly diagnosed with bladder cancer over the last year, of which more than three fourths of patients were expected to have non-muscle-invasive bladder cancer.

Keytruda is already approved for treating a number of cancers including melanoma, lung cancer, head and neck cancer and Hodgkin lymphoma.

Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Aditya Soni

Reuters: Health News

Previous Article

Astronomers race to study mysterious fast radio burst detected in a nearby galaxy

Next Article

Trial opens in case of missing Ocean Beach man whose body was never found

You may also like